LifeVantage Corporation (LFVN) 주식 분석

회사 개요

LifeVantage Corporation is a specialized entity within the consumer defensive sector, specifically operating in the packaged foods industry, where it focuses on the identification, research, development, formulation, and global sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management solutions, pre and pro-biotics, and skin and hair care products. The company's core product portfolio prominently features Protandim, a dietary supplement that serves as its primary revenue driver within this competitive landscape. In terms of scale, the corporation maintains a market capitalization of $51.48M, generating annual revenue of $210.05M with a workforce comprising 232 employees. These financial dimensions indicate that LifeVantage operates as a small-cap enterprise with a modest revenue footprint relative to its industry peers, suggesting a niche market position rather than broad consumer dominance. The combination of a market cap under $52M and revenue just above $200M places the company in a distinct category of smaller, specialized businesses that often rely on high-margin product formulations rather than volume-driven economies of scale.

재무 건전성

The company reported a total revenue of $210.05M over the trailing twelve months, with a net income of $7.86M and an EBITDA of $11.77M, revealing a significant gap between operational earnings and bottom-line profit that points to substantial tax, interest, or other non-operating cost structures. Specifically, the difference between the $11.77M EBITDA and the $7.86M net income highlights the impact of non-operating expenses or taxes on the final profitability, which is further compounded by the current free cash flow of $-454,500. This negative free cash flow suggests a temporary strain on financial flexibility, potentially due to capital expenditures or working capital requirements that exceed operating cash generation in the current period. Analyzing the margin profile shows a gross margin of 78.7%, which indicates highly efficient production and pricing power, contrasted by an operating margin of only 0.5% and a profit margin of 3.7%, signaling that high fixed costs or administrative expenses are eroding the bottom line. On the balance sheet, the company holds $10.18M in cash against $10.69M in debt, resulting in a debt-to-equity ratio of 32.41, which technically classifies the capital structure as highly leveraged despite the cash on hand. However, the current ratio stands at 2.03, indicating a robust short-term liquidity position where current assets are more than double current liabilities, ensuring the ability to meet obligations as they come due. Return on Equity is calculated at 25.0% while Return on Assets sits at 8.5%, metrics that reveal management is generating significant returns on shareholder capital but face challenges in optimizing returns across the total asset base relative to the high leverage present.

밸류에이션 평가

The valuation metrics show a trailing P/E ratio of 6.70 compared to a forward P/E of 6.55, a minimal difference that implies the market does not currently expect a significant acceleration in earnings growth to justify a multiple expansion in the near future. The price-to-book ratio is recorded at 1.56, indicating that the market values the company at roughly 1.56 times its book value, which reflects a moderate premium over the net asset value typically seen in asset-heavy industries but is consistent with light-asset service models. Alternative valuation measures such as the price-to-sales ratio of 0.25 and the EV/EBITDA of 4.41 suggest that the stock is priced at a fraction of its sales revenue and on a very low multiple of earnings before interest, taxes, and depreciation, reflecting a valuation often seen in distressed or cyclical sectors. Regarding price action, the 52-week high is $15.37 and the 52-week low is $3.90, meaning the stock trades significantly below its recent peak but also far above its minimum, reflecting a wide trading range typical of volatile small-cap securities. The beta value is 0.39, which indicates that the stock exhibits low price volatility and moves with significantly less intensity than the broader market, offering a defensive characteristic that aligns with its consumer defensive sector classification.

Growth & Income

The growth trajectory reveals a revenue growth rate of -27.8% year-over-year and an earnings growth rate of -89.5% year-over-year, illustrating that earnings are declining at a much faster pace than revenue, which suggests potential issues with cost control, margin compression, or a sharp contraction in specific product lines driving the bottom line. Regarding income distribution, the company currently offers a dividend yield of 4.5% with a payout ratio of 29.2%, a configuration where the dividend is paid out of earnings but the negative free cash flow and significant earnings decline raise questions about the sustainability of this payout relative to the deteriorating profitability. The high payout ratio combined with negative earnings growth and negative free cash flow indicates that the dividend may be reliant on cash reserves or non-cash accounting adjustments rather than organic cash generation, requiring close monitoring of future cash flow turnaround. Summarizing the overall profile, LifeVantage presents a complex picture of high historical dividend yield and low valuation multiples juxtaposed against significant negative growth trends and negative operating cash flow that investors must weigh carefully against the defensive sector context.